Cargando…
A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE)
BACKGROUND: Disease recurrence is the main cause of mortality after resection of pancreatic ductal adenocarcinoma (PDAC). In 20–30% of resected patients, isolated local PDAC recurrence occurs. Retrospective studies have suggested that stereotactic body radiation therapy (SBRT) might lead to improved...
Autores principales: | van Goor, I. W. J. M., Daamen, L. A., Besselink, M. G., Bruynzeel, A. M. E., Busch, O. R., Cirkel, G. A., Groot Koerkamp, B., Haj Mohammed, N., Heerkens, H. D., van Laarhoven, H. W. M., Meijer, G. J., Nuyttens, J., van Santvoort, H. C., van Tienhoven, G., Verkooijen, H. M., Wilmink, J. W., Molenaar, I. Q., Intven, M. P. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617359/ https://www.ncbi.nlm.nih.gov/pubmed/36307892 http://dx.doi.org/10.1186/s13063-022-06829-1 |
Ejemplares similares
-
Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE)
por: van Goor, I. W. J. M., et al.
Publicado: (2023) -
Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
por: Doppenberg, D., et al.
Publicado: (2022) -
Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design
por: Doppenberg, D., et al.
Publicado: (2023) -
Alternative Randomized Trial Designs in Surgery: A Systematic Review
por: Augustinus, Simone, et al.
Publicado: (2022) -
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)